Last $27.57 USD
Change Today +0.12 / 0.44%
Volume 828.7K
ACAD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 5:20 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Key Developments

Acadia Pharmaceuticals Inc. Receives FDA Breakthrough Therapy Designation for NUPLAZID (Pimavanserin) for Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID (pimavanserin) for the treatment of Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinson's disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application (NDA). ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

ACADIA Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ACADIA Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $21.5 million, or $0.22 per basic and diluted common share compared to a net loss of $9.1 million, or $0.11 per basic and diluted common share, for the second quarter of 2013. Net losses for the second quarters of 2014 and 2013 included $4.3 million and $1.1 million, respectively, in non-cash, stock-based compensation expense. Collaborative revenues were $28,000 compared to $451,000 a year ago. Loss from operations was $21,723,000 compared to $9,157,000 a year ago. For the six months ended June 30, 2014, the company reported a net loss of $39.3 million, or $0.41 per basic and diluted common share, compared to a net loss of $15.2 million, or $0.19 per basic and diluted common share, for the comparable period of 2013. Net losses for the six-month periods ended June 30, 2014 and 2013 included $7.5 million and $1.6 million, respectively, in non-cash, stock-based compensation expense. Collaborative revenues were $58,000 compared to $868,000 a year ago. Loss from operations was $39,681,000 compared to $15,321,000 a year ago.

ACADIA Pharmaceuticals Inc. to Report Q2, 2014 Results on Aug 05, 2014

ACADIA Pharmaceuticals Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 05, 2014

ACADIA Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

ACADIA Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

ACADIA Pharmaceuticals Inc. Appoints Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer

ACADIA Pharmaceuticals Inc. announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective July 15, 2014. Mr. Davis will report to Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry. He most recently served as Executive Vice President and Chief Operating Officer at Heron Therapeutics Inc., which he joined in 2013. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Ardea Biosciences Inc. from 2010 to 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $27.57 USD +0.12

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACAD.
View Industry Companies
 

Industry Analysis

ACAD

Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8,116.0x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7,089.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.